首页> 外文期刊>Cancer letters >Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade
【24h】

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade

机译:ATP结合盒(ABC)家族的哺乳动物药物外排转运蛋白在多药耐药性中的应用:过去十年的回顾

获取原文
获取原文并翻译 | 示例
           

摘要

Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR is the overexpression of ATP-binding cassette (ABC) efflux transporters in cancer cells such as P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated protein 2 (MRP2/ABCC2), and breast cancer resistance protein (BCRP/ABCG2) that limits the prolonged and effective use of chemotherapeutic drugs. Researchers have found that developing inhibitors of ABC efflux transporters as chemosensitizers could overcome MDR. But the clinical trials have shown that most of these chemosensitizers are merely toxic and only show limited or no benefits to cancer patients, thus new inhibitors are being explored. Recent findings also suggest that efflux pumps of the ABC transporter family are subject to epigenetic gene regulation. In this review, we summarize recent findings of the role of ABC efflux transporters in MDR. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
机译:多药耐药性(MDR)是癌细胞使用的一种严重现象,阻碍了癌症药物治疗的成功。 MDR的常见机制之一是癌细胞中ATP结合盒(ABC)外排转运蛋白的过表达,例如P-糖蛋白(P-gp / ABCB1),多药耐药相关蛋白2(MRP2 / ABCC2)和乳腺癌抗癌蛋白(BCRP / ABCG2),限制了化疗药物的长期有效使用。研究人员发现,开发作为化学增敏剂的ABC外排转运蛋白抑制剂可以克服MDR。但是临床试验表明,大多数化学增敏剂仅具有毒性,对癌症患者仅显示出有限的益处,甚至没有显示出任何益处,因此正在研究新的抑制剂。最近的发现还表明,ABC转运蛋白家族的外排泵受到表观遗传基因调控。在这篇综述中,我们总结了ABC外排转运蛋白在MDR中的作用的最新发现。 (C)2015 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号